Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine

Journal of Psychiatric Research

Volumn 44, Issue 14, 2010, Pages 903-909

  Valvassori, Samira S ^a   Rezin, Gislaine T ^a   Ferreira, Camila L ^a   Moretti, Morgana ^a   Gonçalves, Cinara L ^a   Cardoso, Mariana R ^a   Streck, Emílio L ^a   Kapczinski, Flávio ^b   Quevedo, João ^a  

^a UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Amphetamine; Bipolar disorder; Lithium; Mania; Mitochondrial chain; Valproate

Indexed keywords

AMPHETAMINE; DOPAMINE; LITHIUM; SODIUM CHLORIDE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIPOLAR DISORDER; BRAIN REGION; CONTROLLED STUDY; HYPERACTIVITY; MALE; MITOCHONDRIAL RESPIRATION; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; RESPIRATORY CHAIN;

ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN; CORPUS STRIATUM; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DOPAMINE UPTAKE INHIBITORS; ELECTRON TRANSPORT; ELECTRON TRANSPORT COMPLEX I; ELECTRON TRANSPORT COMPLEX II; ELECTRON TRANSPORT COMPLEX III; ELECTRON TRANSPORT COMPLEX IV; HIPPOCAMPUS; LITHIUM COMPOUNDS; LOCOMOTION; MALE; MITOCHONDRIA; MOTOR ACTIVITY; PREFRONTAL CORTEX; RATS; RATS, WISTAR; VALPROIC ACID;

EID: 77955985464     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2010.02.009     Document Type: Article

References (53)

1. Agmo A., Belzung C., Giordano M. Interactions between dopamine and GABA in the control of ambulatory activity. Journal of Neural Transmission 1996, 103:925-934.
2. 2+ signaling. Current Opinion in Neurobiology 1998, 8:398-404.
3. Barrett S.L., Kelly C., Bell R., King D.J. Gender influences the detection of spatial working memory deficits in bipolar disorder. Bipolar Disorders 2008, 10:647-654.
4. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proceedings of the National Academy of Sciences United States of America 2004, 101:5099-5104.
5. Berk M., Dodd S., Kauer-Sant'anna M., Malhi G.S., Bourin M., Kapczinski F., et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatrica Scandinavica Supplementum 2007, 434:41-49.
6. Brookes P.S., Yoon Y., Robotham J.L., Anders M.W., Sheu S.S. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. American Journal of Physiology - Cell Physiology 2004, 287:C817-C833.
7. Burrows K.B., Gudelsky G., Yamamoto B.K. Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4 methylenedioxymethamphetamine administration. European Journal of Pharmacology 2000, 398:11-18.
8. Calabrese V., Scapagnini G., Giuffrida Stella A.M., Bates T.E., Clark J.B. Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochemical Research 2001, 26:739-764.
9. Carli M., Morissette M., Hébert C., Di Paolo T., Reader T.A. Effects of a chronic lithium treatment on central dopamine neurotransporters. Biochemical Pharmacology 1997, 54:391-397.
10. Cassina A., Radi R. Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport. Archives of Biochemistry and Biophysics 1996, 328:309-316.
11. Chuang D.M. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Annals of the New York Academy of Sciences 2005, 1053:195-204.
12. Clark J.B. N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Developmental Neuroscience 1998, 20:271-276.
13. Cott J., Engel J. Suppression by GABAergic drugs of the locomotor stimulation induced by morphine, amphetamine, and apomorphine: evidence for both pre- and post-synaptic inhibition of catecholamine systems. Journal of Neural Transmission 1977, 40:253-268.
14. Davis L.L., Bartolucci A., Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. Journal of Affective Disorders 2005, 85:259-266.
15. El-Mallakh R.S., El-Masri M.A., Huff M.O., Li X.P., Decker S., Levy R.S. Intracerebroventricular administration of ouabain as a model of mania in rats. Bipolar Disorders 2003, 5:362-365.
16. Fischer J.C., Ruitenbeek W., Berden J.A., Trijbels J.M., Veerkamp J.H., Stadhouders A.M., et al. Differential investigation of the capacity of succinate oxidation in human skeletal muscle. Clinica Chimica Acta 1985, 153:23-26.
17. Frey B.N., Andreazza A.C., Ceresér K.M., Martins M.R., Valvassori S.S., Réus G.Z., et al. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Science 2006, 79:281-286.
18. Frey B.N., Martins M.R., Petronilho F.C., Dal-Pizzol F., Quevedo J., Kapczinski F. Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disorders 2006, 8:275-280.
19. Frey B.N., Valvassori S.S., Réus G.Z., Martins M.R., Petronilho F.C., Bardini K., et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. Journal of Psychiatry and Neuroscience 2006, 31:326-332.
20. Frey B.N., Valvassori S.S., Réus G.Z., Martins M.R., Petronilho F.C., Bardini K., et al. Changes in antioxidant defense enzymes after d-amphetamine exposure: implications as an animal model of mania. Neurochemical Research 2006, 31:699-703.
21. Goodwin F.K., Jamison K.R. Manic-depressive illness 1990, vol. 36. Oxford University Press, New York.
22. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO Journal 2001, 20:6969-6978.
23. Gould T.J., Keith R.A., Bhat R.V. Differential sensitivity to lithium's reversal of amphetamine-induced open-field activity in two inbred strains of mice. Behavioural Brain Research 2001, 118:95-105.
24. Iwamoto K., Bundo M., Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Human Molecular Genetics 2005, 14:241-253.
25. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Research Reviews 1991, 16:223-244.
26. Kato T., Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disorders 2000, 2:180-190.
27. Kato T., Kunugi H., Nanko S., Kato N. Mitochondrial DNA polymorphisms in bipolar disorder. Journal of Affective Disorders 2001, 62:151-164.
28. Machado-Vieira R., Kapczinski F., Soares J.C. Perspective for the development of animals models of bipolar disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2004, 28:209-224.
29. Manji H.K., Duman R.S. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacology Bulletin 2001, 35:5-49.
30. Martinez D., Slifstein M., Broft A., Mawlawi O., Hwang D.R., Huang Y., et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. Journal of Cerebral Blood Flow and Metabolism 2003, 23:285-300.
31. Mattiasson G., Shamloo M., Gido G., Mathi K., Tomasevic G., Yi S., et al. Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma. Nature Medicine 2003, 9:1062-1068.
32. Miller T.A., Witter D.J., Belvedere S. Histone deacetylase inhibitors. Journal of Medicinal Chemistry 2003, 46:5097-5116.
33. Munakata K., Iwamoto K., Bundo M., Kato T. Mitochondrial DNA 3243A>G mutation and increased expression of LARS2 gene in the brains of patients with bipolar disorder and schizophrenia. Biological Psychiatry 2005, 57:525-532.
34. Murashita J., Kato T., Shioiri T., Inubushi T., Kato N. Altered brain energy metabolism in lithium-resistant bipolar disorder detected by photic stimulated 31P-MR spectroscopy. Psychological Medicine 2000, 30:107-115.
35. Musavi S., Kakkar P. Diazepam induced early oxidative changes at the subcellular level in rat brain. Molecular and Cellular Biochemistry 1998, 78:41-46.
36. Musavi S., Kakkar P. Pro and antioxidant responses to repeated administration of diazepam in rat brain. Molecular and Cellular Biochemistry 2000, 206:97-103.
37. Musavi S., Kakkar P. Effect of diazepam treatment and its withdrawal on pro/antioxidative processes in rat brain. Molecular and Cellular Biochemistry 2003, 245:51-56.
38. Owens M.J., Nemerroff C.B. Pharmacology of valproate. Psychopharmacology Bulletin 2003, 37:17-24.
39. Pantazopoulos H., Stone D., Walsh J., Benes F.M. Differences in the cellular distribution of D1 receptor mRNA in the hippocampus of bipolars and schizophrenics. Synapse 2004, 54:147-155.
40. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Journal of Biological Chemistry 2001, 276:36734-36741.
41. Post R.M., Weiss S.R. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdale kindled seizures. Molecular Neurobiology 1996, 13:33-60.
42. Quraishi S., Walshe M., McDonald C., Schulze K., Kravariti E., Bramon E., et al. Memory functioning in familial bipolar I disorder patients and their relatives. Bipolar Disorders 2009, 11:209-214.
43. Robinson T.E., Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. Journal of Neuroscience 1997, 17:8491-8497.
44. Rodriquez M., Aquino M., Bruno I., DeMartino G., Taddei M., Gomez-Paloma L. Chemistry and biology of chromatin remodeling agents: state of art and future perspectives of HDAC inhibitors. Current Medicinal Chemistry 2006, 13:1119-1139.
45. Rustin P., Chretien D., Bourgeron T., Gerard B., Rotig A., Saudubray J.M., et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clinica Chimica Acta 1994, 228:35-51.
46. Sandoval M.R., Palermo-Neto J. Effect of manipulation of the GABA system on dopamine-related behaviors. Brazilian Journal of Medical and Biological Research 1995, 28:88-99.
47. Shaldivin A., Kaptsan A., Belmaker R.H., Einat H., Grisaru N. Transcranial magnetic stimulation in an amphetamine hyperactivity model of mania. Bipolar Disorders 2001, 3:30-34.
48. 2+ regulation in neuronal and glial cell signaling. Brain Research Reviews 1997, 26:72-81.
49. Stork C., Renshaw P.F. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Molecular Psychiatry 2005, 10:900-919.
50. Valvassori S.S., Petronilho F.C., Réus G.Z., Steckert A.V., Oliveira V.B., Boeck C.R., et al. Effect of N-acetylcysteine and/or deferoxamine on oxidative stress and hyperactivity in an animal model of mania. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:1064-1068.
51. Vogel M., Pfeifer S., Schaub R.T., Grabe H.J., Barnow S., Freyberger H.J., et al. Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology 2004, 50:305-310.
52. Wallace D.C. Mitochondrial diseases in man and mouse. Science 1999, 283:1482-1488.
53. Yatham L.N., Liddle P.F., Lam R.W., Shiah I.S., Lane C., Stoessl A.J., et al. PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. American Journal of Psychiatry 2002, 159:1718-1723.